ClinicalTrials.gg
CompletedNCT00553696Updated Mar 13, 2015Results posted

Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer

A Phase 1 interventional study of Cisplatin and S-1 in Stomach Neoplasms, sponsored by Pfizer. Completed at 3 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-03-13.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing cisplatin in Stomach Neoplasms — 7 open to participants now, 8 under way, 2 of them phase 3. Cisplatin · Stomach Neoplasms.

Enrollment
73rd of 90
27 · median 48
Started
2007
with 7 others
Phase 1
14 of 98
1 open now
Registered
44th of 98
by date
Lead sponsor
3 of 98
Pfizer

Among the 98 studies testing cisplatin in Stomach Neoplasms, this one is the 73rd largest by enrollment of the 90 interventional ones that give a count, is one of 8 that started in 2007, is one of 14 in phase 1, and was the 44th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

7 of the 98 studies testing cisplatin in Stomach Neoplasms are open now, in 7 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About cisplatin

Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing cisplatin in Stomach Neoplasms, or all of them as a file.
02

Study summary

To assess the maximal tolerated dose (MTD) and overall safety of sunitinib when administered in combination with S-1 and Cisplatin in patients with advanced/metastatic gastric cancer.

03

Conditions studied

  • Stomach Neoplasms

Browse trials for

Keywords

  • chemotherapy
  • combination
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed diagnosis of gastric cancer
  • Chemonaive patients
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Patients who meet the of S-1 and Cisplatin.
  • Prior chemotherapy failure patients
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    A

    Drug: Cisplatin · Drug: S-1 · Drug: Sunitinib

Interventions

  • Cisplatin 60 mg/m2 on day 1 of each 28 day cycle

  • DrugS-1

    Drug pages: Tegafur · Gimeracil · Oxonic Acid

    S-1 80 mg/m2 on days 1-21 of each 28 day cycle

  • Sunitinib 25 mg, 37.5 mg and 50 mg daily S-1 80 mg/m2 on days 1-21 of each 28 day cycle Cisplatin 60 mg/m2 on day 1 of each 28 day cycle

06

What researchers measure

Primary outcomes

  1. Number of Participants With First Cycle Dose-limiting Toxicities (DLTs)

    A DLT is any of a predefined set of unacceptable adverse events, regardless of cause. DLTs were assessed during the first cycle (4 weeks).

    Time frame: Cycle 1 (Baseline to Week 4)

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Sunitinib, SU-012662, and Total Drug (Sunitinib + SU-012662)

    Time frame: Day 1 of Cycles 1 and 2 (pre-dose, 2, 4, 6, 8, 10, and 24 hours post-dose)

  2. Time to Reach Maximum Observed Plasma Concentration (Tmax) of Sunitinib, SU-012662, and Total Drug (Sunitinib + SU-012662)

    Time frame: Day 1 of Cycles 1 and 2 (pre-dose, 2, 4, 6, 8, 10, and 24 hours post-dose)

  3. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Sunitinib, SU-012662, and Total Drug (Sunitinib + SU-012662)

    Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)

    Time frame: Day 1 of Cycles 1 and 2 (pre-dose, 2, 4, 6, 8, 10, and 24 hours post-dose)

  4. Maximum Observed Plasma Concentration (Cmax) of Tegafur and 5-FU

    Time frame: Day 1 of Cycles 1 and 2 (pre-dose, 1, 2, 4, 6, 8, and 10 hours post-dose)

  5. Time to Reach Maximum Observed Plasma Concentration (Tmax) of Tegafur and 5-FU

    Time frame: Day 1 of Cycles 1 and 2 (pre-dose, 1, 2, 4, 6, 8, and 10 hours post-dose)

  6. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Tegafur and 5-FU

    Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)

    Time frame: Day 1 of Cycles 1 and 2 (pre-dose, 1, 2, 4, 6, 8, and 10 hours post-dose)

  7. Maximum Observed Plasma Concentration (Cmax) of Total Platinum and Free Platinum

    Time frame: Day 1 of Cycles 1 and 2 (pre-dose, 0.5, 1, 2, 8, and 22 hours after completing infusion)

  8. Time to Reach Maximum Observed Plasma Concentration (Tmax) of Total Platinum and Free Platinum

    Time frame: Day 1 of Cycles 1 and 2 (pre-dose, 0.5, 1, 2, 8, and 22 hours after completing infusion)

  9. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Total Platinum and Free Platinum

    Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)

    Time frame: Day 1 of Cycles 1 and 2 (pre-dose, 0.5, 1, 2, 8, and 22 hours after completing infusion)

  10. Number of Participants With Objective Response

    Number of participants with objective response-based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). CR defined as the disappearance of all target lesions. PR defined as greater than or equal to (≥) 30 percent (%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. Confirmed responses are those that persist on repeat imaging at least 4 weeks after initial documentation of response.

    Time frame: Baseline up to 739 days

  11. Number of Participants With Clinical Benefit Response (CBR)

    CBR is defined as a confirmed complete response (CR), confirmed partial response (PR), or stable disease (SD) for at least 24 weeks on study according to RECIST. Confirmed responses are those that persist on repeat imaging at least 4 weeks after initial documentation of response.

    Time frame: Baseline up to 739 days

  12. Duration of Response (DR)

    Time from the first objective documentation of tumor response (confirmed or partial response) to first documented objective tumor progression or death due to cancer. DR calculated as (the end date for DR minus first subsequent confirmed CR or PR plus 1 day).

    Time frame: Baseline up to 739 days

  13. Progression-Free Survival (PFS)

    Median time from the enrollment to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first. PFS calculated as (first event date minus enrollment date plus 1 day)

    Time frame: Baseline up to 739 days

  14. Time to Progression (TTP)

    Time in months from enrollment to first documentation of objective tumor progression. TTP was calculated as (first event date or last known progression-free date minus the date of enrollment plus 1 day). Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\] per RECIST).

    Time frame: Baseline up to 739 days

07

Results

Posted Mar 13, 2015

Participant flow

Participant flow — Overall Study
MilestoneSunitinib 25 mg CDD + S-1 + CisplatinSunitinib 25 mg 2/2 + S-1 + Cisplatin (All)Sunitinib 37.5 mg 2/2 + S-1 + CisplatinSunitinib 12.5 mg CDD + S-1 + Cisplatin
Started41661
Completed0000
Not completed41661
Withdrew: Adverse event2401
Withdrew: Global deterioration of health status0200
Withdrew: Objective progression or relapse2960
Withdrew: Withdrawal by subject0100

Outcome measures

PrimaryNumber of Participants With First Cycle Dose-limiting Toxicities (DLTs)

A DLT is any of a predefined set of unacceptable adverse events, regardless of cause. DLTs were assessed during the first cycle (4 weeks).

Time frame:
Cycle 1 (Baseline to Week 4)
Reported as:
Number · participants
Number of Participants With First Cycle Dose-limiting Toxicities (DLTs)
participantsSunitinib 25 mg CDD + S-1 + CisplatinSunitinib 25 mg 2/2 + S-1 + Cisplatin (Dose Escalation Cohort)Sunitinib 37.5 mg 2/2 + S-1 + Cisplatin
Number of Participants With First Cycle Dose-limiting Toxicities (DLTs)213
SecondaryMaximum Observed Plasma Concentration (Cmax) of Sunitinib, SU-012662, and Total Drug (Sunitinib + SU-012662)
Time frame:
Day 1 of Cycles 1 and 2 (pre-dose, 2, 4, 6, 8, 10, and 24 hours post-dose)
Reported as:
Mean · nanogram per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of Sunitinib, SU-012662, and Total Drug (Sunitinib + SU-012662)
nanogram per milliliter (ng/mL)Sunitinib 25 mg 2/2 + Cisplatin + S-1 (MTD Expansion Cohort)
Cycle 1 Day 1: Sunitinib (Sunitinib Alone)14.47 ± 5.3414
Cycle 2 Day 1:Sunitinib (Sunitinib+S-1+Cisplatin)13.14 ± 3.1675
Cycle 1 Day 1: SU-012662 (Sunitinib Alone)2.487 ± 1.1515
Cycle 2 Day 1:SU-012662(Sunitinib+S-1+Cisplatin)2.331 ± 1.2943
Cycle1 Day 1:Total Drug (Sunitinib Alone)16.86 ± 6.3194
Cycle 2 Day 1:Total Drug(Sunitinib+S-1+Cisplatin)15.41 ± 3.7667
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) of Sunitinib, SU-012662, and Total Drug (Sunitinib + SU-012662)
Time frame:
Day 1 of Cycles 1 and 2 (pre-dose, 2, 4, 6, 8, 10, and 24 hours post-dose)
Reported as:
Median · hrs
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Sunitinib, SU-012662, and Total Drug (Sunitinib + SU-012662)
hrsSunitinib 25 mg 2/2 + Cisplatin + S-1 (MTD Expansion Cohort)
Cycle 1 Day 1: Sunitinib ( Sunitinib Alone)5.97 (3.83 to 8.00)
Cycle 2 Day 1: Sunitinib (Sunitinib+S-1+Cisplatin)7.97 (3.97 to 9.93)
Cycle 1 Day 1: SU-012662 ( Sunitinib Alone)8.00 (3.83 to 10.1)
Cycle 2 Day 1: SU-012662 (Sunitinib+S-1+Cisplatin)9.25 (5.97 to 23.8)
Cycle1 Day1:Total Drug ( Sunitinib Alone)5.97 (3.83 to 9.22)
Cycle 2 Day 1:Total Drug (Sunitinib+S-1+Cisplatin)7.92 (3.97 to 9.25)
SecondaryArea Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Sunitinib, SU-012662, and Total Drug (Sunitinib + SU-012662)

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)

Time frame:
Day 1 of Cycles 1 and 2 (pre-dose, 2, 4, 6, 8, 10, and 24 hours post-dose)
Reported as:
Mean · ng*h/mL
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Sunitinib, SU-012662, and Total Drug (Sunitinib + SU-012662)
ng*h/mLSunitinib 25 mg 2/2 + Cisplatin + S-1 (MTD Expansion Cohort)
Cycle 1 Day 1: Sunitinib (Sunitinib Alone)214.6 ± 61.682
Cycle 2 Day 1: Sunitinib (Sunitinib+S-1+Cisplatin)211.9 ± 46.092
Cycle 1 Day 1: SU-012662 (Sunitinib Alone)39.77 ± 12.857
Cycle 2 Day 1: SU-012662 (Sunitinib+S-1+Cisplatin)44.83 ± 24.046
Cycle 1 Day 1: Total Drug (Sunitinib Alone)254.4 ± 70.913
Cycle 2 Day 1:Total Drug (Sunitinib+S-1+Cisplatin)257.0 ± 59.324
SecondaryMaximum Observed Plasma Concentration (Cmax) of Tegafur and 5-FU
Time frame:
Day 1 of Cycles 1 and 2 (pre-dose, 1, 2, 4, 6, 8, and 10 hours post-dose)
Reported as:
Mean · nanogram per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of Tegafur and 5-FU
nanogram per milliliter (ng/mL)Sunitinib 25 mg 2/2 + S-1 + Cisplatin (All)
Cycle 1 Day 1: Tegafur (S-1 + Cisplatin)1500 ± 147.65
Cycle 2 Day 1: Tegafur (Sunitinib+S-1+Cisplatin)1540 ± 184.39
Cycle 1 Day 1: 5-FU (S-1 + Cisplatin)144.4 ± 33.901
Cycle 2 Day 1: 5-FU (Sunitinib+S-1+Cisplatin)105.7 ± 19.318
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) of Tegafur and 5-FU
Time frame:
Day 1 of Cycles 1 and 2 (pre-dose, 1, 2, 4, 6, 8, and 10 hours post-dose)
Reported as:
Median · hrs
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Tegafur and 5-FU
hrsSunitinib 25 mg 2/2 + S-1 + Cisplatin (All)
Cycle 1 Day 1: Tegafur (S-1 + Cisplatin)1.98 (0.917 to 3.98)
Cycle 2 Day 1: Tegafur (Sunitinib+S-1+Cisplatin)2.00 (0.933 to 2.05)
Cycle 1 Day 1:5-FU (S-1 + Cisplatin)2.00 (1.98 to 3.98)
Cycle 2 Day 1: 5-FU (Sunitinib+S-1+Cisplatin)2.05 (2.00 to 4.13)
SecondaryArea Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Tegafur and 5-FU

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)

Time frame:
Day 1 of Cycles 1 and 2 (pre-dose, 1, 2, 4, 6, 8, and 10 hours post-dose)
Reported as:
Mean · ng*h/mL
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Tegafur and 5-FU
ng*h/mLSunitinib 25 mg 2/2 + S-1 + Cisplatin (All)
Cycle 1 Day 1: Tegafur (S-1 + Cisplatin)8314 ± 726.38
Cycle 2 Day 1: Tegafur (Sunitinib+S-1+Cisplatin)9182 ± 819.65
Cycle 1 Day 1: 5-FU (S-1 + Cisplatin)582.4 ± 109.12
Cycle 2 Day 1: 5-FU (Sunitinib+S-1+Cisplatin)494.8 ± 124.14
SecondaryMaximum Observed Plasma Concentration (Cmax) of Total Platinum and Free Platinum
Time frame:
Day 1 of Cycles 1 and 2 (pre-dose, 0.5, 1, 2, 8, and 22 hours after completing infusion)
Reported as:
Mean · nanogram per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of Total Platinum and Free Platinum
nanogram per milliliter (ng/mL)Sunitinib 25 mg 2/2 + S-1 + Cisplatin (All)
Cycle 1 Day 1: Total (S-1 + Cisplatin)1794 ± 140.11
Cycle 2 Day1: Total (Sunitinib+S-1+Cisplatin)1984 ± 72.319
Cycle 1 Day 1: Free (S-1 + Cisplatin)177.8 ± 121.47
Cycle 2 Day 1:Free (Sunitinib+S-1+Cisplatin)186.9 ± 139.45
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) of Total Platinum and Free Platinum
Time frame:
Day 1 of Cycles 1 and 2 (pre-dose, 0.5, 1, 2, 8, and 22 hours after completing infusion)
Reported as:
Median · hrs
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Total Platinum and Free Platinum
hrsSunitinib 25 mg 2/2 + S-1 + Cisplatin (All)
Cycle 1 Day 1: Total (S-1 + Cisplatin)2.65 (2.50 to 2.93)
Cycle 2 Day1: Total (Sunitinib+S-1+Cisplatin)2.68 (2.58 to 2.90)
Cycle 1 Day 1: Free (S-1 + Cisplatin)2.65 (2.50 to 2.83)
Cycle 2 Day 1:Free (Sunitinib+S-1+Cisplatin)2.68 (2.58 to 2.90)
SecondaryArea Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Total Platinum and Free Platinum

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)

Time frame:
Day 1 of Cycles 1 and 2 (pre-dose, 0.5, 1, 2, 8, and 22 hours after completing infusion)
Reported as:
Mean · ng*h/mL
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Total Platinum and Free Platinum
ng*h/mLSunitinib 25 mg 2/2 + S-1 + Cisplatin (All)
Cycle 1 Day 1: Total (S-1 + Cisplatin)29020 ± 2070.5
Cycle 2 Day1: Total (Sunitinib+S-1+Cisplatin)33000 ± 2192.0
Cycle 1 Day 1: Free (S-1 + Cisplatin)967.8 ± 332.03
Cycle 2 Day 1:Free (Sunitinib+S-1+Cisplatin)1154 ± 417.55
SecondaryNumber of Participants With Objective Response

Number of participants with objective response-based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). CR defined as the disappearance of all target lesions. PR defined as greater than or equal to (≥) 30 percent (%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. Confirmed responses are those that persist on repeat imaging at least 4 weeks after initial documentation of response.

Time frame:
Baseline up to 739 days
Reported as:
Number · participants
Number of Participants With Objective Response
participantsSunitinib 25 mg CDD + S-1 + CisplatinSunitinib 25 mg 2/2 + S-1 + Cisplatin (All)Sunitinib 37.5 mg 2/2 + S-1 + CisplatinSunitinib 12.5 mg CDD + S-1 + Cisplatin
Number of Participants With Objective Response2620
SecondaryNumber of Participants With Clinical Benefit Response (CBR)

CBR is defined as a confirmed complete response (CR), confirmed partial response (PR), or stable disease (SD) for at least 24 weeks on study according to RECIST. Confirmed responses are those that persist on repeat imaging at least 4 weeks after initial documentation of response.

Time frame:
Baseline up to 739 days
Reported as:
Number · participants
Number of Participants With Clinical Benefit Response (CBR)
participantsSunitinib 25 mg CDD + S-1 + CisplatinSunitinib 25 mg 2/2 + S-1 + Cisplatin (All)Sunitinib 37.5 mg 2/2 + S-1 + CisplatinSunitinib 12.5 mg CDD + S-1 + Cisplatin
Number of Participants With Clinical Benefit Response (CBR)21240
SecondaryDuration of Response (DR)

Time from the first objective documentation of tumor response (confirmed or partial response) to first documented objective tumor progression or death due to cancer. DR calculated as (the end date for DR minus first subsequent confirmed CR or PR plus 1 day).

Time frame:
Baseline up to 739 days
Reported as:
Median · Months
Duration of Response (DR)
MonthsSunitinib 25 mg CDD + S-1 + CisplatinSunitinib 25 mg 2/2 + S-1 + Cisplatin (All)Sunitinib 37.5 mg 2/2 + S-1 + CisplatinSunitinib 12.5 mg CDD + S-1 + Cisplatin
Duration of Response (DR)5.7 (5.4 to 5.9)10.4 (3.2 to NA)5.0 (4.6 to 5.3)—
SecondaryProgression-Free Survival (PFS)

Median time from the enrollment to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first. PFS calculated as (first event date minus enrollment date plus 1 day)

Time frame:
Baseline up to 739 days
Reported as:
Median · Months
Progression-Free Survival (PFS)
MonthsSunitinib 25 mg CDD + S-1 + CisplatinSunitinib 25 mg 2/2 + S-1 + Cisplatin (All)Sunitinib 37.5 mg 2/2 + S-1 + CisplatinSunitinib 12.5 mg CDD + S-1 + Cisplatin
Progression-Free Survival (PFS)7.1 (6.7 to 7.5)12.5 (6.4 to 16.5)5.8 (4.4 to 7.5)—
SecondaryTime to Progression (TTP)

Time in months from enrollment to first documentation of objective tumor progression. TTP was calculated as (first event date or last known progression-free date minus the date of enrollment plus 1 day). Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\] per RECIST).

Time frame:
Baseline up to 739 days
Reported as:
Median · Months
Time to Progression (TTP)
MonthsSunitinib 25 mg CDD + S-1 + CisplatinSunitinib 25 mg 2/2 + S-1 + Cisplatin (All)Sunitinib 37.5 mg 2/2 + S-1 + CisplatinSunitinib 12.5 mg CDD + S-1 + Cisplatin
Time to Progression (TTP)7.1 (6.7 to 7.5)12.5 (6.4 to 16.5)5.8 (4.4 to 7.5)—

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sunitinib 25 mg CDD + S-1 + Cisplatin—2/4 (50%)4/4 (100%)
Sunitinib 25 mg 2/2 + S-1 + Cisplatin (All)—8/16 (50%)16/16 (100%)
Sunitinib 37.5 mg 2/2 + S-1 + Cisplatin—2/6 (33.3%)6/6 (100%)
Sunitinib 12.5 mg CDD + S-1 + Cisplatin—1/1 (100%)1/1 (100%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventSunitinib 25 mg CDD + S-1 + CisplatinSunitinib 25 mg 2/2 + S-1 + Cisplatin (All)Sunitinib 37.5 mg 2/2 + S-1 + CisplatinSunitinib 12.5 mg CDD + S-1 + Cisplatin
Cerebral infarctionNervous system disorders0/40/160/61/1
Platelet count decreasedInvestigations2/42/160/60/1
Febrile neutropeniaBlood and lymphatic system disorders1/43/162/60/1
Gastrointestinal haemorrhageGastrointestinal disorders1/41/160/60/1
Cholecystitis acuteHepatobiliary disorders1/40/160/60/1
AnaemiaBlood and lymphatic system disorders0/41/160/60/1
Disseminated intravascular coagulationBlood and lymphatic system disorders0/41/160/60/1
NeutropeniaBlood and lymphatic system disorders0/41/160/60/1
BradycardiaCardiac disorders0/41/160/60/1
PyrexiaGeneral disorders0/41/160/60/1
Most frequent other events
Showing 10 of 134
Most frequent other events
EventSunitinib 25 mg CDD + S-1 + CisplatinSunitinib 25 mg 2/2 + S-1 + Cisplatin (All)Sunitinib 37.5 mg 2/2 + S-1 + CisplatinSunitinib 12.5 mg CDD + S-1 + Cisplatin
AnaemiaBlood and lymphatic system disorders1/43/161/61/1
Febrile neutropeniaBlood and lymphatic system disorders0/42/160/61/1
LeukopeniaBlood and lymphatic system disorders0/43/161/61/1
LymphopeniaBlood and lymphatic system disorders0/40/161/61/1
NeutropeniaBlood and lymphatic system disorders0/43/161/61/1
ThrombocytopeniaBlood and lymphatic system disorders0/43/161/61/1
Lacrimation increasedEye disorders0/44/162/61/1
DiarrhoeaGastrointestinal disorders4/48/164/60/1
Dry mouthGastrointestinal disorders0/40/160/61/1
Periodontal diseaseGastrointestinal disorders0/42/160/61/1

Baseline characteristics

Age, Continuous
Age, Continuous(years)Sunitinib 25 mg CDD + S-1 + CisplatinSunitinib 25 mg 2/2 + S-1 + Cisplatin (All)Sunitinib 37.5 mg 2/2 + S-1 + CisplatinSunitinib 12.5 mg CDD + S-1 + CisplatinTotal
Mean60.8 ± 12.856.8 ± 11.454.8 ± 16.664 ± 057.2 ± 12.3
Sex: Female, Male
Sex: Female, Male(Participants)Sunitinib 25 mg CDD + S-1 + CisplatinSunitinib 25 mg 2/2 + S-1 + Cisplatin (All)Sunitinib 37.5 mg 2/2 + S-1 + CisplatinSunitinib 12.5 mg CDD + S-1 + CisplatinTotal
Female23218
Male2134019
08

Study locations

3 sites
  • Aichi cancer center central hospital / Medical Oncology
    Nagoya, Aichi 464-8681, Japan
  • Saku Central Hospital, GI Devision
    Saku, Nagano, Japan
  • Shizuoka Cancer Center
    Suntougun, Shizuoka 411-8777, Japan
09

References and documents

Publications

  • Boku N, Muro K, Machida N, Hashigaki S, Kimura N, Suzuki M, Lechuga M, Miyata Y. Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer. Invest New Drugs. 2014 Apr;32(2):261-70. doi: 10.1007/s10637-013-9948-5. Epub 2013 May 12. PubMed 23665950 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Jul 2009 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2015, 5 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2007
First posted
Nov 4, 2007
Start
Nov 2007
Primary completionActual
Jul 2009
CompletionActual
Mar 2014
Results first posted
Mar 13, 2015
Last update
Mar 13, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00553696
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 4, 2007
Start date
Nov 2007
Primary completion
Jul 2009
Completion
Mar 2014
Results posted
Mar 13, 2015
Last update
Mar 13, 2015

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cisplatin · Sunitinib

Start the discussion